Apigenin Potentiates TRAIL Therapy of Non-small Cell Lung Cancer Via Upregulating DR4/DR5 Expression in a P53-dependent Manner

Overview

Journal Sci Rep

Specialty Science

Date 2016 Oct 19

PMID 27752089

Citations 52

Authors

Minghui Chen

Xueshi Wang

Daolong Zha

Fangfang Cai

Wenjing Zhang

Yan He

Qilai Huang

Hongqin Zhuang

Zi-Chun Hua

Affiliations

Soon will be listed here.

Abstract

Apigenin (APG) is an edible plant-derived flavonoid that shows modest antitumor activities in vitro and in vivo. APG treatment results in cell growth arrest and apoptosis in various types of tumors by modulating several signaling pathways. In the present study, we evaluated interactions between APG and TRAIL in non-small cell lung cancer (NSCLC) cells. We observed a synergistic effect between APG and TRAIL on apoptosis of NSCLC cells. A549 cells and H1299 cells were resistant to TRAIL treatment alone. The presence of APG sensitized NSCLC cells to TRAIL-induced apoptosis by upregulating the levels of death receptor 4 (DR4) and death receptor 5 (DR5) in a p53-dependent manner. Consistently, the pro-apoptotic proteins Bad and Bax were upregulated, while the anti-apoptotic proteins Bcl-xl and Bcl-2 were downregulated. Meanwhile, APG suppressed NF-κB, AKT and ERK activation. Treatment with specific small-molecule inhibitors of these pathways enhanced TRAIL-induced cell death, mirroring the effect of APG. Furthermore, using a mouse xenograft model, we demonstrated that the combined treatment completely suppressed tumor growth as compared with APG or TRAIL treatment alone. Our results demonstrate a novel strategy to enhance TRAIL-induced antitumor activity in NSCLC cells by APG via inhibition of the NF-κB, AKT and ERK prosurvival regulators.

Citing Articles

Apigenin Induces Apoptosis and Inhibits Migration in Human Cholangiocarcinoma Cells.

Kaewmanee M, Limpaiboon T, Ngernyuang N Toxics. 2025; 13(2).

PMID: 39997927 PMC: 11860412. DOI: 10.3390/toxics13020112.

An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway.

Pandey P, Lakhanpal S, Mahmood D, Kang H, Kim B, Kang S Front Pharmacol. 2025; 15():1513422.

PMID: 39834817 PMC: 11743680. DOI: 10.3389/fphar.2024.1513422.

MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle.

Guo J, Zhong L, Momeni M Cell Biol Toxicol. 2024; 40(1):77.

PMID: 39283408 PMC: 11405467. DOI: 10.1007/s10565-024-09920-2.

Chemopreventive Agents from Nature: A Review of Apigenin, Rosmarinic Acid, and Thymoquinone.

Abutayeh R, Altah M, Mehdawi A, Al-Ataby I, Ardakani A Curr Issues Mol Biol. 2024; 46(7):6600-6619.

PMID: 39057035 PMC: 11276303. DOI: 10.3390/cimb46070393.

Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells.

De Wilt L, Sobocki B, Jansen G, Tabeian H, de Jong S, Peters G Cancer Drug Resist. 2024; 7:12.

PMID: 38835345 PMC: 11149110. DOI: 10.20517/cdr.2024.14.

References

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal J . The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008; 8(3):187-98. DOI: 10.2174/156800908784293659. View

Khan T, Sultana S . Apigenin induces apoptosis in Hep G2 cells: possible role of TNF-alpha and IFN-gamma. Toxicology. 2005; 217(2-3):206-12. DOI: 10.1016/j.tox.2005.09.019. View

Dyer M, MacFarlane M, Cohen G . Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol. 2007; 25(28):4505-6. DOI: 10.1200/JCO.2007.13.1011. View

Duiker E, Mom C, de Jong S, Willemse P, Gietema J, van der Zee A . The clinical trail of TRAIL. Eur J Cancer. 2006; 42(14):2233-40. DOI: 10.1016/j.ejca.2006.03.018. View

Chen P, Yang C . Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol. 2008; 181(12):8441-9. DOI: 10.4049/jimmunol.181.12.8441. View

Davies B, Logie A, McKay J, Martin P, Steele S, Jenkins R . AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in.... Mol Cancer Ther. 2007; 6(8):2209-19. DOI: 10.1158/1535-7163.MCT-07-0231. View

Chang D, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart B, Yaish-Ohad S . c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002; 21(14):3704-14. PMC: 125398. DOI: 10.1093/emboj/cdf356. View

Zhuang H, Jiang W, Zhang X, Qiu F, Gan Z, Cheng W . Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions. J Mol Med (Berl). 2012; 91(2):219-35. DOI: 10.1007/s00109-012-0947-3. View

Lee S, Ryu J, Lee K, Woo S, Park J, Yoo J . Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2007; 259(1):39-49. DOI: 10.1016/j.canlet.2007.09.015. View

10.

Zhuang H, Jiang W, Cheng W, Qian K, Dong W, Cao L . Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. Lung Cancer. 2009; 68(1):27-38. DOI: 10.1016/j.lungcan.2009.05.014. View

11.

Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C . European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?. Ann Oncol. 2015; 26(4):779-786. DOI: 10.1093/annonc/mdv001. View

12.

Nicholas C, Batra S, Vargo M, Voss O, Gavrilin M, Wewers M . Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol. 2007; 179(10):7121-7. DOI: 10.4049/jimmunol.179.10.7121. View

13.

Budhraja A, Gao N, Zhang Z, Son Y, Cheng S, Wang X . Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther. 2011; 11(1):132-42. PMC: 4430727. DOI: 10.1158/1535-7163.MCT-11-0343. View

14.

Daniel B, DeCoster M . Quantification of sPLA2-induced early and late apoptosis changes in neuronal cell cultures using combined TUNEL and DAPI staining. Brain Res Brain Res Protoc. 2004; 13(3):144-50. DOI: 10.1016/j.brainresprot.2004.04.001. View

15.

Li-Weber M . Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 2010; 332(2):304-12. DOI: 10.1016/j.canlet.2010.07.015. View

16.

Chou T . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81. DOI: 10.1124/pr.58.3.10. View

17.

Lee W, Chen W, Wang C, Lin W, Tseng T . Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 2007; 226(2):178-91. DOI: 10.1016/j.taap.2007.09.013. View

18.

Schuler M, Green D . Mechanisms of p53-dependent apoptosis. Biochem Soc Trans. 2001; 29(Pt 6):684-8. DOI: 10.1042/0300-5127:0290684. View

19.

Shukla S, Gupta S . Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther. 2006; 5(4):843-52. DOI: 10.1158/1535-7163.MCT-05-0370. View

20.

Chan L, Chou T, Ding H, Chen P, Chiang F, Kuo P . Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim Biophys Acta. 2012; 1820(7):1081-91. DOI: 10.1016/j.bbagen.2012.04.013. View